Amazines Free Article Archive
www.amazines.com - Tuesday, July 16, 2019
Read about the most recent changes and happenings at Amazines.com
Log into your account or register as a new author. Start submitting your articles right now!
Search our database for articles.
Subscribe to receive articles emailed straight to your email account. You may choose multiple categories.
View our newest articles submitted by our authors.
View our most top rated articles rated by our visitors.
* Please note that this is NOT the ARTICLE manager
Add a new EZINE, or manage your EZINE submission.
Add fresh, free web content to your site such as newest articles, web tools, and quotes with a single piece of code!
Home What's New? Submit/Manage Articles Latest Posts Top Rated Article Search
Google
Subscriptions Manage Ezines
CATEGORIES
 Article Archive
 Advertising (133297)
 Advice (160829)
 Affiliate Programs (34734)
 Art and Culture (73673)
 Automotive (145656)
 Blogs (75029)
 Boating (9841)
 Books (17128)
 Buddhism (4124)
 Business (1328337)
 Business News (426310)
 Business Opportunities (366258)
 Camping (10960)
 Career (72763)
 Christianity (15841)
 Collecting (11636)
 Communication (115054)
 Computers (241950)
 Construction (38993)
 Consumer (49679)
 Cooking (17061)
 Copywriting (6567)
 Crafts (18204)
 Cuisine (7538)
 Current Affairs (20383)
 Dating (45774)
 EBooks (19685)
 E-Commerce (48195)
 Education (185189)
 Electronics (83491)
 Email (6390)
 Entertainment (159824)
 Environment (28933)
 Ezine (3039)
 Ezine Publishing (5445)
 Ezine Sites (1554)
 Family & Parenting (110898)
 Fashion & Cosmetics (196384)
 Female Entrepreneurs (11842)
 Feng Shui (130)
 Finance & Investment (310266)
 Fitness (105931)
 Food & Beverages (62851)
 Free Web Resources (7938)
 Gambling (30218)
 Gardening (25085)
 Government (10513)
 Health (629293)
 Hinduism (2206)
 Hobbies (44032)
 Home Business (91544)
 Home Improvement (251324)
 Home Repair (46116)
 Humor (4816)
 Import - Export (5450)
 Insurance (45126)
 Interior Design (29545)
 International Property (3485)
 Internet (190974)
 Internet Marketing (146310)
 Investment (22824)
 Islam (1168)
 Judaism (1357)
 Law (80460)
 Link Popularity (4592)
 Manufacturing (20840)
 Marketing (98750)
 MLM (14136)
 Motivation (18211)
 Music (26999)
 New to the Internet (9476)
 Non-Profit Organizations (4048)
 Online Shopping (129613)
 Organizing (7802)
 Party Ideas (11856)
 Pets (38081)
 Poetry (2234)
 Press Release (12671)
 Public Speaking (5618)
 Publishing (7523)
 Quotes (2407)
 Real Estate (126613)
 Recreation & Leisure (95259)
 Relationships (87450)
 Research (16157)
 Sales (80313)
 Science & Technology (110163)
 Search Engines (23447)
 Self Improvement (153090)
 Seniors (6230)
 Sexuality (35942)
 Small Business (49280)
 Software (82968)
 Spiritual (23461)
 Sports (116075)
 Tax (7658)
 Telecommuting (34064)
 Travel & Tourism (307206)
 UK Property Investment (3118)
 Video Games (13422)
 Web Traffic (11724)
 Website Design (56804)
 Website Promotion (36557)
 World News (1000+)
 Writing (35762)
Author Spotlight
ANISH SAH

My Name is Anish Sah, I am an Internet Marketing and SEO Expert, Social Media Guru and young Entrepr...more
JENNIFER HISIR

The artisans of copperreflections.com have been making handmade copper jewelry and unique gift ideas...more
SHWETA SINGH

This article has been written by a verified author, Shweta Singh. She has been in the business of wr...more
AMIT TIWARI

Amit Tiwari is a Digital marketing expert with over 4 years of experience and a wide variety of know...more
ADRIAN JOELE

I have been involved in nutrition and weight management for over 12 years and I like to share my kn...more


Innovative Therapies and Newer Anti-Cancer Agents are Encouraging Clinical Trials in Relapsed CLL: by Ankur Gupta





Article Author Biography
Innovative Therapies and Newer Anti-Cancer Agents are Encouraging Clinical Trials in Relapsed CLL: by
Article Posted: 10/22/2018
Article Views: 300
Articles Written: 1063
Word Count: 543
Article Votes: 0
AddThis Social Bookmark Button

Innovative Therapies and Newer Anti-Cancer Agents are Encouraging Clinical Trials in Relapsed CLL:


 
Health
Leukemia is defined as cancer of blood cells that degenerates the death of damaged cells in a human body. Leukemia is categorized into two types such as myeloid leukemia and lymphocytic leukemia. Myeloid leukemia occurs in the myeloid cells and lymphocytic leukemia occurs during the early formation time of the lymphocytes in the bone marrow. Lymphocytic leukemia is further segregated into chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL). Chronic lymphocytic leukemia (CLL) is a common type of leukemia found in adults where white blood cells develop in the bone marrow and travel through the blood. The preferred treatment for chronic lymphocytic leukemia is chemotherapy and stem-cell transplant is used in rare cases. Various Chimeric Antigen Receptor (CAR) T-Cell therapies are developed for leukemia which increases the effectiveness against cancer cells. According to the study “Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2018”, relapsed or progressive chronic lymphocytic leukemia (CLL) is considered chronic except by allogeneic stem cell transplantation. All chemotherapy and antibody therapies are considered palliative or for the relief of CLL symptoms. Relapsed CLL is highly responsive to a wide variety of treatments and patients sometimes survive for many years with repeated treatment. Clinical trials in relapsed chronic lymphocytic leukemia (CLL) are performed to evaluate the effectiveness of new drugs or treatment strategies. It was estimated that there is a need for development of more effective treatments involving new and innovative therapies. Relapsed CLL is rarely curable and treatment strategies are currently directed at prolonging how long patients can live with cancer. Documented clinical studies of relapsed CLL predict that patients may survive an average of 3-5 years in first phase of clinical trial. However, the disease resurfaces and with each successive therapy within the clinical trials, the response rate decreased and the duration of remission has shortened than that achieved with the prior treatment. Many re-treatment options are available for recurrent CLL until the patient collapses completely. Clinical trials are carried out on patients with relapsed CLL and are treated with single agents keeping in view of other health conditions. Few patients were treated with combined medications which has projected a safe profile within the clinical trials. Several steps of medication are administered to improve the survival and well being of patients suffering from relapsed CLL. The inclusion of new anti-cancer agents into the treatment of relapsed CLL has encouraged many clinical trials. Therefore, there are several active explorations focussed at improving the treatment of relapsed CLL. Geographically, the global relapsed chronic lymphocytic leukemia market is spread across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The leading companies that are conducting clinical trials on relapsed or progressive chronic lymphocytic leukemia (CLL) are AbbVie Inc, F. Hoffmann-La Roche Ltd, Celgene Corp, Novartis AG, Johnson & Johnson, AstraZeneca Plc, Gilead Sciences Inc, GlaxoSmithKline Plc, Bristol-Myers Squibb Co and Sanofi. Increasing incidences of cancer across the globe, innovative drug therapy, fast regulatory approval process, and increasing clinical trials for relapsed CLL are the key factors that support the global clinical trials for relapsed chronic lymphocytic leukemia (CLL) over the next few years. To know more, click on the link below: https://www.kenresearch.com/healthcare/pharmaceuticals/relapsed-chronic-lymphocytic/154883-91.html Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications sales@kenresearch.com +91-9015378249


Related Articles - Relapsed CLL Global Clinical Trials Review Phase by Phase, Relapsed Chronic Lymphocytic Leukemia Global Clinical Trials Review Status,

Email this Article to a Friend!

Receive Articles like this one direct to your email box!
Subscribe for free today!

 Rate This Article  
Completely useless, should be removed from directory.
Minimal useful information.
Decent and informative.
Great article, very informative and helpful.
A 'Must Read'.

 

Do you Agree or Disagree? Have a Comment? POST IT!

 Reader Opinions 
Submit your comments and they will be posted here.
Make this comment or to the Author only:
Name:
Email:
*Your email will NOT be posted. This is for administrative purposes only.
Comments: *Your Comments WILL be posted to the AUTHOR ONLY if you select PRIVATE and to this PUBLIC PAGE if you select PUBLIC, so write accordingly.
 
Please enter the code in the image:



 Author Login 
LOGIN
Register for Author Account

 

Advertiser Login

 

ADVERTISE HERE NOW!
   Limited Time $60 Offer!
   90  Days-1.5 Million Views  

 

Great Paranormal Romance

World News


STEPHEN BYE

Steve Bye is currently a fiction writer, who published his first novel, ‘Looking Forward Through The...more
LANCE CHAPMAN

An experienced, resourceful and highly motivated IT professional, with a proven record of success in...more
GENE MYERS

Author of four books and two screenplays; frequent magazine contributor. I have four other books "in...more
STEVERT MCKENZIE

Stevert Mckenzie, Travel Enthusiast. ...more
LAURA JEEVES

At LeadGenerators, we specialise in content-led Online Marketing Strategies for our clients in the t...more
ANITA WAGGONER

Anita Waggoner grew up in a small town in Eastern Washington. She attended business-college in the S...more
SUSAN FRIESEN

Susan Friesen, founder of the award-winning web development and digital marketing firm eVision Media...more
KIRAN KAUR

Kiranpreet (Kiran) Kaur, D.D.S., who received her Doctor of Dental Surgery degree from the prestigio...more
MICHAEL MIFSUD

Michael Mifsud was a House of Commons Commonwealth correspondent at the age of 16. He published Brit...more
TREENA MURPHY

Warm greetings to you!! Hello there, my name is Treena (Smiley) Murphy I am a part time blogge...more

HomeLinksAbout UsContact UsTerms of UsePrivacy PolicyFAQResources
Copyright © 2019, All rights reserved.
Some pages may contain portions of text relating to certain topics obtained from wikipedia.org under the GNU FDL license